|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-5-9
|
|
pubmed:abstractText |
The purpose of this study was to determine the dose-limiting toxicities (DLTs), the maximum tolerated dose, and the pharmacokinetics of the novel glutathione analog TLK286 administered by i.v. infusion.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BoulosLenyL,
pubmed-author:BrownGail LGL,
pubmed-author:BrownJosephJ,
pubmed-author:DombroskiJacqueline AJA,
pubmed-author:GomezReinaldo FRF,
pubmed-author:HennerWilliam DWD,
pubmed-author:KeckJames GJG,
pubmed-author:LaxaBernadetteB,
pubmed-author:LumRobert TRT,
pubmed-author:MaackChristopher ACA,
pubmed-author:MascavageJulie CJC,
pubmed-author:ReiswigLauraL,
pubmed-author:RosenLee SLS,
pubmed-author:SchowSteve RSR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1628-38
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12738715-Adult,
pubmed-meshheading:12738715-Aged,
pubmed-meshheading:12738715-Cytotoxins,
pubmed-meshheading:12738715-Dose-Response Relationship, Drug,
pubmed-meshheading:12738715-Female,
pubmed-meshheading:12738715-Glutathione,
pubmed-meshheading:12738715-Humans,
pubmed-meshheading:12738715-Infusions, Intravenous,
pubmed-meshheading:12738715-Male,
pubmed-meshheading:12738715-Maximum Tolerated Dose,
pubmed-meshheading:12738715-Middle Aged,
pubmed-meshheading:12738715-Neoplasm Recurrence, Local,
pubmed-meshheading:12738715-Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
|
|
pubmed:affiliation |
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
